FDA accepts application for proposed biosimilar to Rituxan

08:42 EDT 3 Jul 2017 | Healio

The FDA has accepted a biologics license application for Celltrion Inc. and Teva’s CT-P10, a proposed biosimilar to Rituxan, for the treatment of rheumatoid arthritis, granulomatosis with polyangiitis, microscopic polyangiitis, chronic lymphocytic leukemia and non-Hodgkin’s lymphoma, according to a company press release.“As the global leader in biosimilars who brought Inflectra, the world’s first [monoclonal antibody] mAb biosimilar approved by the FDA, to the U.S., we are pleased and honored to have this opportunity to once again work with the FDA on CT-P10,” Woo Sung Kee, chief executive officer of Celltrion, said in the release. “CT-P10, which has been approved in the [European Union] E.U., is continuing to build a solid track record since its launch there earlier this year and has provided patients with access to a high-quality treatment option and has offered great savings in health care costs. I am hopeful that CT-P10 will bring similar benefits to the [United States] U.S. when approved.”

Original Article: FDA accepts application for proposed biosimilar to Rituxan


More From BioPortfolio on "FDA accepts application for proposed biosimilar to Rituxan"

Quick Search


Relevant Topics

The field encompassing therapeutic materials produced using biological means, including recombinant DNA technology. Biotherapeutics, also known as biotech drugs or biologics, are therapies derived from living organisms. By harnessing these living cells...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...